Hemispherx's (HEB) Ampligen Lacks Required Carcinogenicity Tests - FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Join SI Premium – FREE
Hemispherx Biopharma, Inc. (AMEX: HEB) Ampligen lacks required carcinogenicity tests, according to the FDA.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic transcatheter valve linked to serious injury report
- Immunome gets EMA validation for varegacestat in desmoid tumors
- FDA extends Agios mitapivat sickle cell review to February 2027
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
